Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency.

CONCLUSION: Four once-weekly doses of NNC0195-0092 (dose range 0.02-0.12 mg/kg) administered to adult patients with GHD were well tolerated and IGF-I profiles were consistent with a once-weekly treatment profile. No clinically significant safety and tolerability signals causally related to NNC0195-0092 were identified, nor were any immunogenicity concerns revealed.
PMID: 26727076 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - January 4, 2016 Category: Endocrinology Authors: Rasmussen MH, Janukonyté J, Klose M, Marina D, Tanvig M, Nielsen LF, Höybye C, Andersen M, Feldt-Rasmussen U, Christiansen JS Tags: J Clin Endocrinol Metab Source Type: research